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Abstract The aim of this study was to divide the group of
triple-negative breast cancer patients with brain metastases
into basal-like and non-basal-like biological subtypes in
order to compare clinical features and survival rates in
those two groups. A comprehensive analysis of 111 con-
secutive triple-negative breast cancer patients with brain
metastases treated in the years 2003–2009 was performed.
In 75 patients, immunohistochemistry was used as a sur-
rogate of microarray in order to evaluate the expression of
three basal markers: cytokeratin 5/6 (CK 5/6), EGFR/
HER1 and c-KIT. The basal-like (ER/PgR/HER2-negative,
CK5/6positive and/or HER1-positive) and non-basal-like
(ER/PgR/HER2-negative, CK5/6-negative, HER1-nega-
tive) subsets were selected. Clinical features and survivals
were compared in both groups. In the group of 111 triple-
negative breast cancer patients, median DFS, OS and sur-
vival from brain metastases were 20, 29 and 4 months,
respectively. In 75 patients who were evaluable for basal
markers, median DFS, OS and survival from brain metas-
tases were 18, 26 and 3.2 months, respectively. In the
basal-like subtype, the survival rates were 15, 26 and
3 months, respectively, and in the non-basal-like subtypes,
they were 20, 30 and 2.8 months, respectively. No statis-
tically signiﬁcant differences in survivals were detected
between the basal-like and non-basal-like biological sub-
types. Factors inﬂuencing survival from brain metastases
were: Karnofsky performance status (KPS), the status of
extracranial disease and age. Biological markers differen-
tiating triple-negative group into basal-like and non-basal-
like subtype (CK 5/6, HER1, c-KIT) had no inﬂuence on
survival. In patients with triple-negative breast cancer and
brain metastases, well-known clinical, but not molecular,
features correlated with survival.
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Introduction
Triple-negative breast cancer represents a distinct subset of
breast cancer that exhibits a more aggressive course as
compared to other biological subtypes of cancer [1–7]. The
aggressiveness of the disease is best illustrated by the fact
that the peak risk of recurrence of the disease is between
the ﬁrst and third year following diagnosis, and that sur-
vival after recurrence is signiﬁcantly shorter than that
observed in patients with non-triple-negative controls [4, 6,
8–10]. Surprisingly, patients who did not have a recurrence
of the disease within the ﬁrst 8 years after the diagnosis did
not subsequently relapse. However, in other subtypes of
breast cancer, the risk of recurrence keeps rising as time
progresses [4, 11]. The recurrence pattern of triple-negative
breast cancer also differs from other biological subtypes of
cancer. In addition, the most characteristic sites of metas-
tases include the brain and lungs [3, 6, 12].
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DOI 10.1007/s11060-011-0616-3From a biological point of view, triple-negative breast
cancer remains a heterogeneous group with difﬁcult-to-
deﬁne subtypes. Gene expression studies have shown that
ER-negative and HER2-negative tumors are clustered into
at least three distinct molecular classes: basal-like, normal-
like and claudin-negative breast cancer [1, 11, 13–19].
Most of triple-negative tumors show basal-like phenotype
which can be subdivided into pure variant and myoepi-
thelial variant [20]. Many ‘‘immunohistochemical (IHC)
signatures’’ have been described as a surrogate of micro-
array, but the panel proposed by Nielsen et al. [21] seems
to be the best example of the classiﬁcation to date. In this
classiﬁcation, basal-like cancers are deﬁned as those
lacking ER and HER2 expression and expressing cyto-
keratin 5/6 (CK 5/6) and/or Epidermal Growth Factor
Receptor (EGFR or HER1). This panel has 100% speci-
ﬁcity and 76% sensitivity for identiﬁcation of basal-like
cancers.
Patients with triple-negative breast cancer and brain
metastases have the poorest prognosis out of all biological
subtypes of breast cancer after dissemination to the brain
[3]. It is not known whether such a short survival depends
on clinical features (performance status, dissemination of
the disease to other organs), or the afﬁliation to the speciﬁc
biological subset, which can be selected by molecular
markers, for example basal cytokeratins.
The aim of the present study was to analyze clinical
features and survival of triple-negative breast cancer
patients with brain metastases and to compare basal-like
and non-basal-like subtypes in order to establish the clin-
ical value of basal biological markers differentiating these
subtypes.
Materials and methods
Between 1 January 2003 and 31 December 2009, 111
patients with triple-negative (ER-negative, PgR-negative,
HER2-negative) breast cancer and brain metastases were
treated in the Breast Cancer and Reconstructive Surgery
Department at The Maria Sklodowska-Curie Memorial
Cancer Center, Warsaw, Poland. The observation of the
patients started at the time of the detection of brain
metastases and all data were collected prospectively in our
database. In each case, treatment options were approved by
a team of medical oncologists, radiation oncologist, neu-
rologist and neurosurgeon, and were performed after
patients had signed written consent. Immunohistochemistry
(IHC) was carried out in order to evaluate levels of ER,
PgR and HER2 expression in primary breast tumors.
Staining was performed using primary antibodies against
ER (Clone 6F11, Novocastra, dilution scale 1:100); against
PR (Clone 16, Novocastra, dilution scale 1:200) and
against HER2 (Polyclonal Hercep Test, DAKO). For the
evaluation of ER and PR expression, all cases with 10% or
higher stained cancer nuclei were classiﬁed as positive.
Fluorescence in situ hybridization (FISH) was used for all
HER2 2? tumors using the HER2 DNA Probe Kit Abbott
(Vysis). HER2-positive staining was deﬁned as IHC 3? or,
in the case of IHC 2?, FISH-positive. HER2-negativity
was deﬁned as IHC 0, 1? or 2?, along with negative FISH
results.
Immunohistochemistry for cytokeratin 5/6 (Clone D5/
16B4, DAKO, dilution scale 1:100), HER1 (EGFR pharm
Dx, Clone 2-18C9, DAKO, RTU) and c-KIT (CD117,
Policlonal, DAKO, dilution scale 1:500), as a surrogate of
cDNA microarray, was performed in 75 patients in whom
parafﬁn blocs with primary tumor samples were available
in the pathology archives. These assays were performed
after the detection of brain metastases. Based on the deﬁ-
nition by Nielsen et al. [21], tumors were divided into
basal-like and non-basal-like biological subsets.
In 36 out of 111 patients, the analysis of basal markers
was impossible to perform for the following reasons:
ﬁrstly, there was an insufﬁcient amount of biological
material to perform detailed analysis. In some of those
patients, only core biopsy or ﬁne needle biopsy was per-
formed to conﬁrm the initial diagnosis of breast cancer
and, after detection of brain metastases, we did not have
enough biological material to perform IHC analysis. Sec-
ondly, some patients were treated in different hospitals
before the dissemination of the disease, and after the
detection of brain metastases, it was impossible to gain
access to parafﬁn blocks from their primary tumors.
Thirdly, according to information provided by the
remaining patients, the IHC was impossible to perform
due to technical difﬁculties that occurred during patho-
logical processing.
Statistical analysis
Descriptive statistics were used to determine patient
demographics and clinical characteristics. In order to
compare categorical tumor features in the basal-like and
non-basal-like subsets, the chi-square test was used. For
those categorical variables in which the chi-square test was
inappropriate because of small sample size, the Fisher
exact test was used. A univariate analysis and Cox pro-
portional hazards model were developed to identify factors
inﬂuencing survival after brain metastasis in patients with
triple-negative breast cancer. The following factors were
analyzed in a Cox model: KPS (\70 vs. C70), age at
detection of brain metastases (\50 vs. C50), extracranial
disease (absent vs. present), extracranial disease (con-
trolled vs. uncontrolled), lung metastases (absent vs. pres-
ent), brain metastases as the ﬁrst or the only metastatic site
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123(yes vs. no), neurosurgery (yes vs. no), systemic treatment
after brain metastases (yes vs. no), basal subtype vs. non-
basal subtype. Disease-free survivals (DFS), overall sur-
vivals (OS, from initial diagnosis of breast cancer), and
survivals from the detection of brain metastases in the
entire group and in biological subgroups were estimated
using the Kaplan–Meier method and compared using the
log-rank test.
Results
Clinical characteristics of the entire group are presented in
Table 1. In the group of 111 patients, histopathology and
metastatic spread that is typical for triple-negative breast
cancer was revealed. In most of the patients, ductal cancer
with histological grade 3 was detected, although medullary
and metaplastic cancers were also found. Lungs and brain
were the most relevant sites of distant metastases. Among
75 patients in whom basal markers were assessed, 48
(64%) tumors expressed CK5/6, 26 (36%) tumors expres-
sed HER1 and 13 (17%) expressed c-KIT. In 6 tumors
(8%), expression of three basal biological markers was
detected and 13 tumors (17%) did not express any of them.
Based on the deﬁnition by Nielsen et al. [21], basal-like
tumors were identiﬁed based on panel of four antibodies
(ER, HER2, HER1 and cytokeratin 5/6). There were 57
patients (76%) with basal-like and 18 (24%) with non-
basal-like biological subtypes. The comparison between
basal-like and non-basal-like subsets is presented in
Table 2. There were no signiﬁcant differences between
both groups in relation to patients’ age at initial diagnosis,
clinical stage and tumor histologic grade; however,
medullar and metaplastic cancers were observed only in the
basal-like subset. Bone metastases, liver metastases and
brain metastases as a ﬁrst site of dissemination were all
equally distributed in both groups, but lung metastases
were more common in the non-basal subtype.
DFS, OS and survival from brain metastases in triple-
negative, basal-like and non-basal-like subsets are pre-
sented in Table 3. In the entire group of 111 triple-negative
breast cancer patients with brain metastases, median DFS,
OS and survival from brain metastases were 20, 29 and
4 months, respectively. In 75 patients with known basal
markers, median DFS, OS and survival from brain metas-
tases were 18, 26 and 3.2 months, respectively. In the
basal-like subtype, they were 15, 26 and 3 months,
respectively, and in the non-basal-like subtype they were
20, 30 and 2.8 months, respectively. No statistically sig-
niﬁcant differences in DFS, OS and survival from brain
metastases were detected between basal-like and non-
basal-like biological subtypes.
The analysis of factors inﬂuencing survival from brain
metastases in triple-negative breast cancer patients with
brain metastases, including clinical and biological factors
was assessed in univariate and multivariate analysis. The
results of univariate analysis of the group of 111 patients
are presented in Table 4. The results of Cox multivariate
analysis (ﬁnal model) is presented in Table 5. Multivariate
analysis revealed that clinical, and not biological factors
inﬂuenced survival from brain metastases. They included
KPS and the status of extracranial metastases. Patients with
good performance status and those with controlled extra-
cranial disease lived longer. Age at the detection of brain
metastases was a factor of borderline signiﬁcance; younger
patients lived longer. None of three analyzed basal markers
(CK 5/6, HER1, c-KIT) had any inﬂuence on survival from
brain metastases.
Table 1 Characteristics of 111 patients with triple-negative breast
cancer patients with brain metastases
Characteristic No. of patients %
Initial TNM stage
I1 8 1 6
II 45 41
III 39 35
IV 9 8
Histological type
Ductal carcinoma 78 70
Lobular carcinoma 2 1
Medullar carcinoma 3 3
Papillar carcinoma 1 1
Mucinous carcinoma 1 1
Metaplastic carcinoma 1 1
Neuroendocrine carcinoma 1 1
Cancer cells or invasive cancer after
Chemotherapy 24 22
Number of brain metastases
12 7 2 4
2 7 6.5
3 6 5.5
Multiple 71 64
Localization of metastases
Brain as the ﬁrst or only site 36 32
Liver 19 17
Lung 54 49
Bone 27 24
Locoregional recurrence 34 31
Neurosurgery 20 18
Systemic therapy after WBRT
a,b 59 53
a WBRT whole-brain radiation therapy
b In most patients, several lines of chemotherapy were used
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123Table 2 Differences in clinical
features between patients with
basal-like (ER/PgR/HER2-
negative, CK5/6-positive and/or
HER1-positive) and non-basal-
like (ER/PgR/HER2-negative,
CK5/6-negative and HER1-
negative) biological subtypes of
triple-negative breast cancer (75
patients)
Factor Basal-like subtype (%)
(ER/PgR/HER2-negative,
CK5/6-positive and/or
HER1-positive)
Non-basal-like subtype (%)
(ER/PgR/HER2-negative,
CK5/6-negative and
HER1-negative)
P value
Number of patients 57 (76%) 18 (24%)
Age at initial diagnosis (years) 50 47 0.343
Age at brain metastases (years) 54 50 0.495
KPS
\70 28 (49%) 6 (33%)
C70 29 (51%) 12 (67%) 0.184
Initial TNM stage
I 8 (14%) 0
II 20 (35%) 10 (56%)
III 23 (40%) 7 (39%)
IV 6 (11%) 1 (5%) 0.062
Histological type and grade
Ductal carcinoma Grade 3 30 (55%) 10 (59%)
Other 25 (45%) 7 (41%) 0.49
Number of brain metastases
1 13 (23%) 4 (22%)
2 3 (5%) 1 (6%)
3 3 (5%) 0
Multiple 38 (67%) 13 (72%) 1.0
Brain as the ﬁrst/only site 20 (35%) 4 (22%) 0.308
Extracranial metastases 37 (65%) 15 (83%) 0.116
Lung metastases 22 (39%) 13 (72%) 0.013
Liver metastases 9 (16%) 2 (11%) 0.447
Bone metastases 15 (26%) 3 (17%) 0.310
Loca/locoregional recurrence 14 (25%) 7 (39%) 0.200
Neurosurgery of brain metastasis 12 (21%) 1 (6%) 0.120
Systemic treatment after WBRT 29 (51%) 11 (61%) 0.314
c-KIT 9 (16%) 4 (22%) 0.575
Table 3 Median survival of
patients with triple-negative
breast cancer (75 patients),
basal-like subtype (57 patients)
and non-basal-like subtype (18
patients)
No. of patients Median survival
(months)
95% CI P-value
Disease-free survival
Triple-negative 75 18 13.728; 21.600
Basal-like 57 15 10.764; 19.308
Non-basal-like 18 20 8.892; 31.560 0.284
Overall survival
Triple-negative 75 26 17.172; 34.248
Basal-like 57 24 17.292; 31.428
Non-basal-like 18 30 19.188; 40.764 0.227
Survival from brain metastases
Triple-negative 75 3.2 2.532; 3.900
Basal-like 57 3.2 2.904; 3.528
Non-basal-like 18 2.8 0.000; 5.892 0.880
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123Discussion
Clinical features
Clinical characteristics of the entire group of 111 triple-
negative breast cancer patients with brain metastases
conﬁrm the results of our previous studies [2, 3] and are
similar to the results of other authors [6, 8, 12, 21, 22].
Due to the fact that we still do not know the biological
or molecular factors that are responsible for dissemination
to the brain and poor survival after the detection of brain
metastases, we tried to ﬁnd out if basal markers could play
a major role in this processes. So we compared clinical
features and survival of patients with triple-negative
tumors and brain metastases which expressed and did not
express basal markers. Because it was not possible to
perform DNA microarray, we used IHC as a surrogate of
molecular analysis. In our material, CK 5/6 was expressed
in 64% of tumors. These results are in line with the ﬁndings
of Nielsen et al. [21], Livacy et al. [23] and Kreike et al.
[16]. HER1 was expressed in 36% of tumors and it is also
in agreement with the literature; HER1 was expressed in up
to 66% of basal-like and triple-negative breast cancers, but
HER1 responsible for activating gene mutations were
remarkably rare [16, 21, 24–26]. The third basal marker,
c-KIT was expressed in 17% of tumors. It was less than in
the study by Nielsen et al. [21] and Kreike [16]. In our
material, the proportion of patients with basal-like and non-
basal-like phenotypes was 76% and 24%, respectively.
This result was comparable to that observed by other
authors [13, 14, 18, 19, 25, 27]. However, in some papers,
the percentage of patients with the basal-like subtype was
about 50% [24].
There are few data in the literature concerning differ-
ences between basal-like and non-basal-like subtypes of
triple-negative breast cancer according to clinical features
and survival. To our knowledge, the present study is the
ﬁrst one analyzing such relationships in patients with brain
metastases. We did not observe statistically signiﬁcant
differences between basal-like and non-basal-like subtypes
apart from the pattern of distant metastases. Rakha et al.
[13] compared the clinicopathological and immunohisto-
chemical features of triple-negative tumors depending on
the expression of speciﬁc basal markers. The authors did
not show any difference in morphological features between
both subtypes, but basal-like breast cancer showed distinct
immunophenotypical differences with the expression of
several markers of poor prognosis [13]. In addition, the
authors observed a unique pattern of distant metastases of
Table 4 Factors inﬂuencing survival from brain metastases in
patients with triple-negative breast cancer: univariate analysis (111
patients)
Covariate Median time
(months)
P value
KPS
\70 2.2
C70 6.3 \0.0001
Age at initial diagnosis
\50 3.3
50–65 3.9
[65 3.6 0.692
Age at the detection of brain metastases
\50 6.3
50–65 3.0
[65 3.6 0.024
Initial TNM stage
I ? II 3.3
III ? IV 4.8 0.158
Extracranial disease
Present 3.2
Absent 6.3 0.063
Extracranial disease
Controlled (stable/responsive) 8.2
Uncontrolled (progressive) 2.8 \0.0001
Locoregional recurrence
Present 4.2
Absent 2.8 0.304
Lung metastases
Present 3.1
Absent 6.3 0.045
Neurosurgery
Yes 12
No 3.2 0.002
Systemic treatment after WBRT
Yes 4.9
No 2.6 0.148
Type of chemotherapy after WBRT
With capecitabine 3.1
With vinorelbine 5.9
With taxanes 5.4
With antracyclines 9.8
With platinum salts or etoposide 3.9
Without chemotherapy 2.6 0.496
Table 5 Cox multivariate analysis of factors inﬂuencing survival
from brain metastases, ﬁnal model
Covariate HR P value 95% CI
Karnofsky performance status
KPS C 70
0.319 \0.0001 0.181; 0.563
Age at brain metastases[50 1.681 0.059 0.981; 2.881
Controlled extracranial disease 0.383 0.001 0.222; 0.660
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123the basal-like subtype with more frequent metastasis to
brain and lung. Such observations were similar to our
observations. In the present study, in 35% of patients with
the basal-like phenotype, the brain was the ﬁrst site of
distant metastasis. The high propensity of the basal-like
phenotype to metastasize to the brain as the ﬁrst site of
distant recurrence is worth further molecular investigation.
It is possible that some molecular markers allow anchor
cancer cells into the brain (theory of ‘‘soil and seed’’). If we
knew such a molecular marker, we would be able to select
a group of breast cancer patients with high risk of brain
metastases in order to take preventive or screening
activities.
Survivals
In the present study, median DFS of all patients with triple-
negative breast cancer with brain metastases was less than
2 years (20 months) and OS was less than 3 years
(29 months). The results are comparable to the results by
Lin et al. [22] in which median DFS of patients with triple-
negative breast cancer was 19.9 months and 75% of
recurrences occurred within 3 years of the diagnosis of
breast cancer. Our previous study concerning 222 patients
with breast cancer and brain metastases revealed statisti-
cally signiﬁcant differences in median OS of patients with
triple-negative, HER2-positive and ER/PR-positive HER2-
negative breast cancer. The differences were as follows:
2.8, 4.3 and 5.4 years, respectively, [3]. In the study by
Dent et al. [4], median OS of triple-negative breast cancer
was 4.2 years compared with 6 years for patients with
other subtypes, and DFS was 2.6 years compared with
5 years in the other biological subtypes. In the present
study, median survival from brain metastases in triple-
negative breast cancer patients was 4 months. The results
conﬁrm our previous observations [2, 3] and are compa-
rable to the study done by Lin et al. [22], in which median
survival time from brain metastases was 4.9 months.
The differences in survival between patients with basal-
like and non-basal-like breast cancer have been assessed in
some studies, but the results were not unequivocal. In some
of them, basal-like breast cancer patients had a signiﬁ-
cantly shorter DFS than those lacking the expression of
basal markers [24, 25]. In the other studies, patients with
basal-like breast cancer had signiﬁcantly shorter DFS and
OS times than women with other biological types of breast
cancer, but basal-like status was not a signiﬁcant inde-
pendent prognostic variable of OS in the multivariate
analysis [28, 29]. In the study by Rakha et al. [13], the
difference in survival between basal-like and non-basal-
like subtypes was assessed in two independent cohorts of
triple-negative breast cancer patients. In the ﬁrst cohort of
232 patients, after the time of observation of 207 months,
the basal-like subtype was associated with shorter DFS, but
not OS. In the second cohort of 67 triple-negative breast
cancer patients, there was no signiﬁcant difference in sur-
vival between those expressing basal markers and those not
expressing them.
In the present study, a very homogenous group of triple-
negative breast cancer patients with brain metastases was
assessed. This group had the worst prognosis out of all
breast cancer patients because of the poorest biological
subtype and the poorest site of dissemination. We did not
show statistically signiﬁcant differences in DFS, OS and
survival from brain metastases which could depend on the
expression of basal markers. Cox multivariate analysis
revealed that the risk of death from brain metastases
depends on well-known clinical features, but not on bio-
logical factors. These results are in agreement with some
published data [3, 29]. The role of KPS and the status of
extracranial disease has been conﬁrmed in our [3] and other
studies [29]. It is possible that, in the group with such poor
outcome, molecular markers are less important than strong
clinical prognostic factors. However, the small number of
patients was a serious limitation of our study and that is
why our results require conﬁrmation by other authors.
Conclusions
Triple-negative breast cancer with brain metastases is a
highly selected type of cancer with very poor prognosis.
The recurrence of the disease occurs within 2 years and
overall survival is less than 3 years. Basal-like and non-
basal-like subgroups of patients with brain metastases did
not differ signiﬁcantly with regards to clinical features and
survival except for the pattern of metastatic spread. Factors
inﬂuencing survival from brain metastases were KPS and
the status of the extracranial disease. Age at the detection
of brain lesions was of borderline signiﬁcance. Searching
for other biological markers responsible for metastatic
spread to the brain is of special value.
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